CDChristopher Darr

Christopher Darr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Darr has a total of 341 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating NECTIN4 Amplification with Membranous NECTIN4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma

    by Niklas Klümper, Thomas Büttner, Sebastian Rauch, Stefanie Zschäbitz, Florian Roghmann, Christian Bolenz, Fabienne Lange, Patricia Rausch, Friedemann Zengerling, Nadine Gaisa, et al.

    Purpose: Enfortumab vedotin (EV) is standard therapy for metastatic urothelial carcinoma (mUC), yet the predictive relevance of Nectin cell adhesion molecule 4 (NECTIN4) expression—especially membranous versus cytoplasmic—remains unclear. In this study, we sought to extend previous findings on NECTIN4 gene amplification in parallel with a systematic subcellular evaluation of Nectin-4 expression. Experimental Design: We retrospectively analyzed 179 EV-treated patients with mUC. NECTIN4 amplification was assessed by fluorescence in situ hybridization (FISH) and Nectin-4 protein levels by immunohistochemistry (IHC). A four-tier membranous scoring algorithm (0, 1+, 2+, and 3+) adapted from the College of American Pathologists (CAP) HER2 gastric guidelines was benchmarked against H-score. We integrated amplification status with membranous staining to refine predictive stratification and compared associations with objective response rate (ORR) with those observed in EV-301 data. Results: Combining membranous and cytoplasmic compartments resulted in a median composite H-score of 260 (78.2% ≥ 150), closely matching Nectin-4 expression prevalence reported in EV-301 (median, 250; 82.6% ≥ 150). A ≥150 cutoff enriched for EV responders in both cohorts, with an ORR of 45.8% versus 20% (P = 0.001) in EV-301. High membranous expression based on the scoring (2+/3+) predicted response (ORR, 55.1% vs. 25.5%; P < 0.001), with longer progression-free survival [PFS; 7.1 vs. 2.9 months; hazard ratio (HR) = 0.45] and overall survival (OS; 12.3 vs. 6.9 months; HR = 0.57), whereas cytoplasmic expression lacked predictive value. NECTIN4-amplified tumors showed particularly favorable outcomes (PFS, 12.2 months; OS, 30.1 months). An integrated three-tier model—amplified, nonamplified/high-membranous, and nonamplified/low-membranous—yielded ORRs of 77.2%, 42.9%, and 26.1% and separated survival outcomes. Conclusions: Our Nectin-4 scoring system integrating NECTIN4 amplification with membranous Nectin-4 expression accurately predicts outcomes, supporting combined genomic and membranous assessment as complementary biomarkers for optimizing EV selection. See related article by YYY, p. XX .


  • Open Access

    Sexual function after prostate cancer surgery or radiotherapy in an international registry

    by Y. Hess-Busch, C. Darr, L. Püllen, M. Al-Nader, M. Wahl, A. V. Bailey, H. Wilhalme, J. Lee, B. Hadaschik, J. Hess, et al.

    Objectives: Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods: This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry. Patients with baseline and 12‐month patient‐reported outcome measures after radical prostatectomy (RP), external beam radiotherapy (EBRT) ± androgen‐deprivation therapy (ADT), or brachytherapy (BT) were included. SF was assessed using the EPIC‐26 sexual function domain score (SFDS). Baseline and 12‐month EPIC‐26 SFDS were compared by treatment group, with additional analyses among RP patients examining outcomes by intent to nerve spare and sexual aid use. Linear regression, adjusted for age, National Comprehensive Cancer Network risk group, baseline SFDS, and intent to nerve spare was used to identify predictors of 12‐month SFDS among surgery patients. Results: Overall, 13 413 men were analysed (RP 85.2%, EBRT only 9.1%, EBRT+ADT 4.3%, BT 1.3%). SF declined significantly across all modalities. Median SFDS reduction was greatest after RP (−60.0%) and smallest after BT (−40.2%). At 12 months, poor or absent erectile function was reported by 63.6–91.8% of patients, highest after RP and EBRT+ADT. Sexual aid use increased after treatment but remained low overall. Given the retrospective design and non‐representative sites in an international registry setting, these findings should be interpreted as associational rather than causal because of the potential for unmeasured confounding and cross‐country heterogeneity in treatment selection. Conclusion: All curative PC treatments were associated with substantial deterioration in SF. These findings support enhanced pre‐treatment counselling and early integration of proactive management and structured sexual rehabilitation into survivorship care.

  • Open Access

    Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

    by Lars Drüke, Jessica Schmitz, Manuel M. Vicente, Nikolaos Vasileiadis, David Christensen, Melanie Maulhardt, Markus A. Kuczyk, Hossein Tezval, Christopher Darr, Viktor Grünwald, et al.

  • Open Access

    Histotype-specific incidence and survival of urothelial carcinoma—an analysis of the German North Rhine-Westphalia Cancer Registry

    by C. Darr, L. Möller, A. Szentkiralyi, K. Claassen, N. Schürger, H. Reis, T. Hilser, A. Stang, B.A. Hadaschik, H. Kajüter, et al.

  • Open Access

    Predictors of Biochemical Recurrence in Patients with Positive Surgical Margin After Radical Prostatectomy

    by Osama Mahmuod, Mulham Al-Nader, Andreas Grevendieck, Ulrich Krafft1, Christopher Darr, Lukas Puellen, Jan Philipp Radtke, Andrej Panic

    Objective: To investigate the predictors of biochemical recurrence (BCR) in patients with positive surgical margins (PSMs) after radical prostatectomy (RP). Methods: The data of patients who underwent open RP between 2003 and 2011 were reviewed. Only patients with PSM and negative lymph node invasion were considered for further analysis. Multivariable Cox regression analysis was performed to evaluate the correlation between clinicopathologic criteria and BCR. Results: Out of 116 patients, 80 (69%) developed BCR with a median (interquartile range [IQR]) time to recurrence of 19 (9-50) months. Median (IQR) time of follow-up in non-recurrent patients was 121 (47-148) months. The 5- and 10-year BCR-free survival rates were 43% and 28%, respectively. Complete data regarding margin parameters were available only for 98 patients, of which 71 (72%) developed BCR. Univariable analysis demonstrated that prostate volume (PV) (HR 0.97, 95% CI 0.95-0.99, P = .005), highest Gleason grade (GG) at the margin (HR 1.73, 95% CI: 1-2.83, P = .028 for GG 4-5 vs. 3), tumor GG group 2 (HR [Hazard Ratio] 2, 95% CI 1.09-3.94, P = .025) and 4-5 (HR 2.34, 95% CI 1-4.98, P = .028) were significant predictors of BCR. In multivariable analysis, only PV remained an independent predictor of BCR (HR 0.98, 95% CI 0.96-0.99, P = .03). Conclusion: In patients with PSM after RP, smaller prostates have a higher probability of BCR. Further studies are needed to investigate this association. The highest GG at the margin has important predictive accuracy and should be reported in the pathol ogy report. Cite this article as: Mahmuod O, Al-Nader M, Grevendieck A, et al. Predictors of biochemical recurrence in patients with positive surgical margin after radical prostatectomy. Urol Res Pract. 2025;51(5):198-202.

  • Open Access

    Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

    by Niklas Klümper, Damian J. Ralser, Jörg Ellinger, Florian Roghmann, Julia Albrecht, Eduard Below, Abdullah Alajati, Danijel Sikic, Johannes Breyer, Christian Bolenz, et al.

    Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.

  • Open Access

    Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

    by Niklas Klümper, Damian J. Ralser, Jörg Ellinger, Florian Roghmann, Julia Albrecht, Eduard Below, Abdullah Alajati, Danijel Sikic, Johannes Breyer, Christian Bolenz, et al.

    Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic metastasis; LYM=non-locoregionary lymph node metastasis; OSS=bone metastasis; OTH= metastasis at other locations including soft tissue; PER=peritoneal metastasis; PUL=pulmonary metastasis.

  • Open Access

    Supplementary Data TS2 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

    by Niklas Klümper, Damian J. Ralser, Jörg Ellinger, Florian Roghmann, Julia Albrecht, Eduard Below, Abdullah Alajati, Danijel Sikic, Johannes Breyer, Christian Bolenz, et al.

    Supplementary Table 2. Baseline characteristics of the multicenter EV cohort.

  • Open Access

    Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis

    by R. Stelmach, S. Erdmann, K. Schlack, C. Muehle, C. Darr, S. Neuberger, M. Reichert, L. Flegar, T. Egenolf, M. Rehlinghaus, et al.


  • Open Access

    Establishing Medical Intelligence—Leveraging Fast Healthcare Interoperability Resources to Improve Clinical Management: Retrospective Cohort and Clinical Implementation Study

    by Alexander Brehmer, Christopher Martin Sauer, Jayson Salazar Rodríguez, Kelsey Herrmann, Moon Kim, Julius Keyl, Fin Hendrik Bahnsen, Benedikt Frank, Martin Koehrmann, Tienush Rassaf, et al.

    Background: FHIR (Fast Healthcare Interoperability Resources) has been proposed to enable health data interoperability. So far, its applicability has been demonstrated for selected research projects with limited data. Objective: This study aimed to design and implement a conceptual medical intelligence framework to leverage real-world care data for clinical decision-making. Methods: A Python package for the use of multimodal FHIR data (FHIRPACK [FHIR Python Analysis Conversion Kit]) was developed and pioneered in 5 real-world clinical use cases, that is, myocardial infarction, stroke, diabetes, sepsis, and prostate cancer. Patients were identified based on the ICD-10 (International Classification of Diseases, Tenth Revision) codes, and outcomes were derived from laboratory tests, prescriptions, procedures, and diagnostic reports. Results were provided as browser-based dashboards. Results: For 2022, a total of 1,302,988 patient encounters were analyzed. (1) Myocardial infarction: in 72.7% (261/359) of cases, medication regimens fulfilled guideline recommendations. (2) Stroke: out of 1277 patients, 165 received thrombolysis and 108 thrombectomy. (3) Diabetes: in 443,866 serum glucose and 16,180 glycated hemoglobin A1c measurements from 35,494 unique patients, the prevalence of dysglycemic findings was 39% (13,887/35,494). Among those with dysglycemia, diagnosis was coded in 44.2% (6138/13,887) of the patients. (4) Sepsis: In 1803 patients, Staphylococcus epidermidis was the primarily isolated pathogen (773/2672, 28.9%) and piperacillin and tazobactam was the primarily prescribed antibiotic (593/1593, 37.2%). (5) PC: out of 54, three patients who received radical prostatectomy were identified as cases with prostate-specific antigen persistence or biochemical recurrence. Conclusions: Leveraging FHIR data through large-scale analytics can enhance health care quality and improve patient outcomes across 5 clinical specialties. We identified (1) patients with sepsis requiring less broad antibiotic therapy, (2) patients with myocardial infarction who could benefit from statin and antiplatelet therapy, (3) patients who had a stroke with longer than recommended times to intervention, (4) patients with hyperglycemia who could benefit from specialist referral, and (5) patients with PC with early increases in cancer markers.